In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
  • Year

    Select Year(s)

  • Session Type

    Select Session Type(s)

  • Resource type

    Select Resource type(s)

  • Topic

    Select Topic(s)

Filters (0)
  • sub-topic
  • Year
  • Session Type
  • Resource type
  • Topic
  • sub-topic
  • Year
  • Session Type
  • Resource type
  • Topic

Sponsored content

Presentations below are part of sessions sponsored by Novartis Pharma AG

79 results for your search

2018

Advancing standard of care in post-myocardial infarction (MI) patients with elevated high sensitivity C-reactive protein (hsCRP).

Congress : EuroPrevent 2018

  • Session : Inflammation in atherosclerosis: translating science into practicable solutions.
  • Speaker : U Landmesser (Berlin,DE), P Libby (Boston,US), W Koenig (Munich,DE)
  • Sponsored by Novartis Pharma AG

Some member-only content

2018

Audience Q&A and panel discussion.

Congress : ESC Congress 2018

  • Session : Emerging evidence-based approaches to reduce residual atherosclerotic risk
  • Speaker : W Koenig (Munich,DE), P Libby (Boston,US), P M Ridker (Boston,US), J H Cornel (Alkmaar,NL)
  • Sponsored by Novartis Pharma AG

Some member-only content

days left for free access
2018

Clinical residual cardiovascular risk: what are the markers?

Congress : EuroPrevent 2018

  • Session : Inflammation in atherosclerosis: translating science into practicable solutions.
  • Speaker : W Koenig (Munich,DE)
  • Sponsored by Novartis Pharma AG

Some member-only content

2018

Emerging evidence-based approaches to reduce residual atherosclerotic risk - ask the experts.

Congress : ESC Congress 2018

  • Session : Emerging evidence-based approaches to reduce residual atherosclerotic risk - Ask the experts
  • Speaker : P M Ridker (Boston,US), A Catapano (Milan,IT)
  • Sponsored by Novartis Pharma AG

Some member-only content

days left for free access
2018

Hospital admission for heart failure: an opportunity to optimize heart failure therapy?

Congress : ESC Congress 2018

  • Session : Seize the moment to optimize treatment for each patient with heart failure: why, when, and how
  • Speaker : R Wachter (Leipzig,DE)
  • Sponsored by Novartis Pharma AG

Some member-only content

days left for free access
2018

Identification of residual inflammatory cardiovascular risk.

Congress : ESC Congress 2018

  • Session : Emerging evidence-based approaches to reduce residual atherosclerotic risk
  • Speaker : J H Cornel (Alkmaar,NL)
  • Sponsored by Novartis Pharma AG

Some member-only content

days left for free access
2018

Inflammation in atherosclerosis: time for translation?

Congress : ESC Congress 2018

  • Session : Emerging evidence-based approaches to reduce residual atherosclerotic risk
  • Speaker : P Libby (Boston,US)
  • Sponsored by Novartis Pharma AG

Some member-only content

days left for free access
2018

Inflammation in atherosclerosis: translating science into practicable solutions.

Congress : EuroPrevent 2018

  • Session : Inflammation in atherosclerosis: translating science into practicable solutions.
  • Speaker : P Libby (Boston,US)
  • Sponsored by Novartis Pharma AG

Some member-only content

2018

Introduction - Seize the moment to optimize treatment for each patient with heart failure: why, when, and how.

Congress : ESC Congress 2018

  • Session : Seize the moment to optimize treatment for each patient with heart failure: why, when, and how
  • Speaker : B Pieske (Berlin,DE)
  • Sponsored by Novartis Pharma AG

Some member-only content

days left for free access
2018

Learning points and close - Emerging evidence-based approaches to reduce residual atherosclerotic risk.

Congress : ESC Congress 2018

  • Session : Emerging evidence-based approaches to reduce residual atherosclerotic risk
  • Speaker : W Koenig (Munich,DE)
  • Sponsored by Novartis Pharma AG

Some member-only content

days left for free access

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are